Cargando…

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data

BACKGROUND: Little is known about disease trajectories for men with castration-resistant prostate cancer (CRPC). OBJECTIVE: To create a state transition model that estimates time spent in the CRPC state and its outcomes. DESIGN, SETTING, AND PARTICIPANTS: The model was generated using population-bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ventimiglia, Eugenio, Bill-Axelson, Anna, Adolfsson, Jan, Aly, Markus, Eklund, Martin, Westerberg, Marcus, Stattin, Pär, Garmo, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520495/
https://www.ncbi.nlm.nih.gov/pubmed/36185582
http://dx.doi.org/10.1016/j.euros.2022.07.010
_version_ 1784799637525233664
author Ventimiglia, Eugenio
Bill-Axelson, Anna
Adolfsson, Jan
Aly, Markus
Eklund, Martin
Westerberg, Marcus
Stattin, Pär
Garmo, Hans
author_facet Ventimiglia, Eugenio
Bill-Axelson, Anna
Adolfsson, Jan
Aly, Markus
Eklund, Martin
Westerberg, Marcus
Stattin, Pär
Garmo, Hans
author_sort Ventimiglia, Eugenio
collection PubMed
description BACKGROUND: Little is known about disease trajectories for men with castration-resistant prostate cancer (CRPC). OBJECTIVE: To create a state transition model that estimates time spent in the CRPC state and its outcomes. DESIGN, SETTING, AND PARTICIPANTS: The model was generated using population-based prostate-specific antigen data from 40% of the Swedish male population, which were linked to nationwide population-based databases. We compared the observed and predicted cumulative incidence of transitions to and from the CRPC state. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured time spent in the CRPC state and the proportion of men who died of prostate cancer during follow-up by CRPC risk category. RESULTS AND LIMITATIONS: Time spent in the CRPC state varied from 1.1 yr for the highest risk category to 3.9 yr for the lowest risk category. The proportion of men who died from prostate cancer within 10 yr ranged from 93% for the highest risk category to 54% for the lowest. There was good agreement between the model estimates and observed data. CONCLUSIONS: There is large variation in the time spent in the CRPC state, varying from 1 yr to 4 yr according to risk category. PATIENT SUMMARY: It is possible to accurately estimate the disease trajectory and duration for men with castration-resistant prostate cancer.
format Online
Article
Text
id pubmed-9520495
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95204952022-09-30 Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data Ventimiglia, Eugenio Bill-Axelson, Anna Adolfsson, Jan Aly, Markus Eklund, Martin Westerberg, Marcus Stattin, Pär Garmo, Hans Eur Urol Open Sci Prostate Cancer BACKGROUND: Little is known about disease trajectories for men with castration-resistant prostate cancer (CRPC). OBJECTIVE: To create a state transition model that estimates time spent in the CRPC state and its outcomes. DESIGN, SETTING, AND PARTICIPANTS: The model was generated using population-based prostate-specific antigen data from 40% of the Swedish male population, which were linked to nationwide population-based databases. We compared the observed and predicted cumulative incidence of transitions to and from the CRPC state. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured time spent in the CRPC state and the proportion of men who died of prostate cancer during follow-up by CRPC risk category. RESULTS AND LIMITATIONS: Time spent in the CRPC state varied from 1.1 yr for the highest risk category to 3.9 yr for the lowest risk category. The proportion of men who died from prostate cancer within 10 yr ranged from 93% for the highest risk category to 54% for the lowest. There was good agreement between the model estimates and observed data. CONCLUSIONS: There is large variation in the time spent in the CRPC state, varying from 1 yr to 4 yr according to risk category. PATIENT SUMMARY: It is possible to accurately estimate the disease trajectory and duration for men with castration-resistant prostate cancer. Elsevier 2022-08-23 /pmc/articles/PMC9520495/ /pubmed/36185582 http://dx.doi.org/10.1016/j.euros.2022.07.010 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Prostate Cancer
Ventimiglia, Eugenio
Bill-Axelson, Anna
Adolfsson, Jan
Aly, Markus
Eklund, Martin
Westerberg, Marcus
Stattin, Pär
Garmo, Hans
Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
title Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
title_full Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
title_fullStr Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
title_full_unstemmed Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
title_short Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
title_sort modeling disease trajectories for castration-resistant prostate cancer using nationwide population-based data
topic Prostate Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520495/
https://www.ncbi.nlm.nih.gov/pubmed/36185582
http://dx.doi.org/10.1016/j.euros.2022.07.010
work_keys_str_mv AT ventimigliaeugenio modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT billaxelsonanna modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT adolfssonjan modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT alymarkus modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT eklundmartin modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT westerbergmarcus modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT stattinpar modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata
AT garmohans modelingdiseasetrajectoriesforcastrationresistantprostatecancerusingnationwidepopulationbaseddata